Clovis Oncology - 51 Year Dividend History | CLVSQ

Historical dividend payout and yield for Clovis Oncology (CLVSQ) since 1971. The current TTM dividend payout for Clovis Oncology (CLVSQ) as of December 20, 2022 is $0.00. The current dividend yield for Clovis Oncology as of December 20, 2022 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.149B
Clovis Oncology, Inc. is a biopharmaceutical companyfocused on acquiring, developing and commercializing innovative anti-cancer agents.?Clovis has only one marketed drug in its portfolio a poly ADP-ribose polymerase inhibitor, namely Rubraca that is approved for the treatment of certain patients with ovarian and prostate cancer.?Currently, Rubraca is approved in the United States for two indications specific to ovarian cancer in the second and third or later-line setting. The drug is also approved in the United States under accelerated approval as monotherapy for treating BRCA-mutant metastatic castrate-resistant prostate cancer.?A broad development program on Rubraca is currently underway across a variety of solid tumors. Clovis is looking to expand Rubraca's label into additional cancer types like breast and gastroesophageal cancers, among others. Meanwhile, Clovis holds global development and commercialization rights to Rubraca.
Stock Name Country Market Cap PE Ratio